Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value of the enzyme replacement therapy business only, BioMarin has limited near-term value-drivers and “competitive overhangs” on Voxzogo, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target raised to $116 from $104 at Canaccord
- BioMarin price target lowered to $119 from $120 at Morgan Stanley
- BioMarin price target raised to $120 from $110 at Evercore ISI
- BioMarin price target lowered to $82 from $94 at Bernstein
- BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged